Objectives. The objectives of this study were to (1) compare the prevalence of smoking within chronic pain patients (CPPs) to community non-patients without pain (CNPWP), community patients with pain (CPWP), and acute pain patients (APPs); and (2) compare smokers to nonsmokers within CPPs, APPs, and CPWP for highest pain level.
Introduction
A large number of studies have addressed the issue of whether smoking is a risk factor for chronic low back pain (LBP). These studies have been reviewed by a number of researchers [1] [2] [3] [4] [5] . In the first review, Heliövaara [1] reviewed 50 cross-sectional retrospective studies and concluded that smoking is associated with increased risk for LBP, but its causal role was questionable. Six years later, this literature was again reviewed by Leboeuf-Yde [2, 3] . She found consistent evidence against a causal association between smoking and sciatica/discal herniation. Four years later, Lebooeuf-Yde again reexamined this literature [4] . This time, she found some signs of causality consistently evident in large studies and concluded that smoking should be considered a weak risk factor for LBP. In the fifth review, Goldberg et al. [5] concluded that the data were consistent in indicating that smoking is associated with the incidence and prevalence of nonspecific LBP. The most recent review was a meta-analysis [6] , where 80 studies were reviewed, and 40 were included. Current and former smokers were found to have a higher prevalence and incidence of LBP than those who have never smoked, but that association was fairly modest [6] .
There is also evidence from cross-sectional general population studies that smoking is associated with frequent pain in six locations [7] , chronic pain [8] , pain in three or more locations [9] , more pain locations [10] , and a higher risk of having pain at all sites considered (low back, neck, upper, and lower limbs) [11] . Overall, these two lines of evidence suggest that the prevalence of smokers within chronic pain patients (CPPs) should be greater than in comparison populations. In reference to this question, there are limited data. The Tobacco Supplement to the National Comorbidity Survey has determined that the lifetime prevalence for nicotine dependence in the United States is 20.9% [12] . One study in CPPs has reported the prevalence of smoking (not nicotine addiction) to be 54% [13] , while another has reported a prevalence of 37.6% [14] . Three cross-sectional studies have found the prevalence of smoking to be increased within CPPs [8, 15, 16] . To our knowledge, there is no other information on this question.
Investigating the above question rests on comparing the prevalence of smoking within CPPs to appropriate control groups, but we were only able to find one such study. Here, rheumatoid arthritis patients were found to have a statistically lower prevalence of smoking than fibromyalgia patients [17] . Consequently, the first goal of the present study is to compare the prevalence of smoking within CPPs to community non-patients without pain (CNPWP), community patients with pain (CPWP), and acute pain patients (APPs).
The second question we wished to investigate was whether smoking CPPs have higher pain levels than nonsmoking CPPs. Here, there are a few cross-sectional studies in general populations that indicate smokers complain of higher pain than nonsmokers [10, 18, 19] . Within specific populations, the studies are not consistent. Here, smoking cancer patients have been reported to complain of more pain than nonsmoking cancer patients [20] [21] [22] . Four studies from pain centers have reported smoking CPPs to complain of higher pain than nonsmoking CPPs [23] [24] [25] [26] , while three others have not [14, 27, 28] . As a result, it is presently not clear if smoking CPPs have higher pain levels or not. As such, the study described below compares smokers to nonsmokers within CPPs, CPWP, and APPs for highest pain level.
Methods

Subjects/Participants
This study is based on items from a data pool of 600 items/questions previously utilized to develop the Battery for Health Improvement 2 (BHI 2). The data pool items were collected between 1/95 and 9/95. The BHI 2 is made up of a subset of items from this data pool [29] . The present study deals with two items from this data pool. These items were a smoking item (nonsmoker, less than one pack per day, and one pack/day or more) and a horizontal 0-10 numerical rating scale (NRS) where patients were asked to rate their highest pain in the last month from 0 (no pain) to 10 (worst pain you can imagine).
The data pool items had been administered to 777 patients undergoing rehabilitation treatment for pain or a physical injury in 30 states in all geographical regions of the continental United States. The participants who were recruited by posters or flyers given to them by their health care providers came from a variety of settings: physical therapy, work hardening programs, chronic pain programs, physician offices, and vocational rehabilitation settings. The patients were from various payor systems (Medicare/Medicaid, private insurance, worker's compensation, and personal injury insurance). Their nonspecific and specific diagnoses are presented here as a percentage of the total rehabilitation patient group (N = 777) (some patients had more than one diagnosis): Headache pain 12.2% (N = 95); whiplash-associated pain 6.8% (N = 53); non-whiplash cervical sprain-associated pain 8.1% (N = 63); upper extremity injury-associated pain 25.2% (N = 196); low back injury-associated pain 44.4% (N = 345); lower extremity injury-associated pain 25.4% (N = 197); head injury-associated pain 11.2% (N = 87); carpal tunnel syndrome 6% (N = 47); thoracic outlet syndrome 2.2% (N = 17); reflex sympathetic dystrophy 1.4% (N = 11); and fibromyalgia 1.4% (N = 11). These nonspecific and specific diagnoses were received from the treating facilities either before referral to the facility or during treatment. We have no information as to what types of physicians assigned these diagnoses. Of these 777 rehabilitation patients, 667 reported experiencing pain (numerical rating scale [NRS] score highest pain greater than zero), and 110 had no pain. Of patients with pain, 341 suffered from chronic pain (CPPs; greater than 90 days duration). The remaining patients (N = 326) had acute pain (APPs; less than 90 days duration).
A community healthy group (N = 1,329; responding "No" to the item "Do you have a serious medical condition?") and a community non-healthy group (N = 158; responding "Yes" to the item "Do you have a serious medical condition?") were also administered the 600 data pool items. These subjects were from 16 states in all four geographical areas of the United States. They were recruited by newspaper advertisements and posters; stratified according to race, education, age, and gender; and recruited to match these demographics. No subject was excluded on the basis of past or present medical or psychological diagnoses [29] . Of the community healthy group, 129 had no pain whatsoever and became the community nonpatients without pain (CNPWP). Of the community nonhealthy, 108 had pain and became the community patients with pain (CPWP) group.
Instrumentation
The 600 data pool items are not an inventory and contain no scales; therefore, they have no associated reliability and validity data. However, each item had 1-week testretest reliability scores. The two items under investigation had test-retest reliability scores of 0.99 (smoking) and 0.934 (highest pain). Some data pool items have been found to be associated with some interesting clinical issues (violent ideation against physicians, hostility, suing physicians, treatment adherence, illness uncertainty, anger, homicide-suicide thoughts, suicidality) [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] .
Data Collection Procedures
Participation for all groups was by self-selection; subjects were reimbursed for their participation. Any patient or subject wishing to participate in the data pool collection study was allowed study entrance. The only exclusion criteria were being less than 18 years or over 65 and not being able to read the data pool items. The data pool items were administered in a confidential manner (questionnaires were assigned a random ID number). No records were kept regarding which ID number a patient or non-patient was assigned; the data were processed by persons having no contact with, or knowledge of, the respondents (data were de-identified). All groups signed an informed consent form advising the subjects/patients of the risks and benefits of participation in completing the data pool items. The consent form indicated that the information would be used for research purposes only, one of those being to develop a new questionnaire for medical patients. The consent form also indicated that no results or feedback would be given; the information gathered from the data pool items would not influence the course of clinical care of those patients under clinical care. The consent form had been developed by an internal committee at Pearson Assessments, reviewed and approved by an external institutional review board (IRB). The committee monitored the implementation of the data gathering and reported to the external IRB. The data pool set was presented for BHI 2 development in a de-identified format, and years later, also in a de-identified format for further analysis as in this study. The total number of subjects administered the data pool items was 2,487. Of these, 223 subjects were eliminated from the study for the following reasons: One subject did not sign the informed consent form; 41 subjects had missing age or gender, or had listed contradictory age or genders; and 57 subjects failed to complete the assigned forms. Finally, while all the subjects were administered the data pool items, some were also administered the MMPI-2 or MCMI-3 tests. If the subject had an invalid profile on any of these tests, the subject was eliminated from the data pool. Overall, invalid protocols eliminated 124 additional subjects. This left 2,264 subjects with complete information and valid test protocols.
Data Analysis
Data were analyzed using SPSS 19 (IBM Inc., Chicago, IL, USA) for Windows and Zumastat (Applied Scientific Analysis, Miami, FL, USA). The relative risk of being 1) a nonsmoker, 2) smoking less than one pack per day, 3) smoking one pack or more per day, or 4) smoking any amount per day was calculated for the following comparisons: 1) CNPWP (reference group) vs CPWP, APPs, and CPPs; 2) CPWP (reference group) vs APPs and CPPs; and 3) APPs (reference group) vs CPPs. Thus, relative risk is equal to the probability of the occurrence of an event in one group compared to the probability of the occurrence of the same event in another group, e.g., the relative risk of being a smoker between CNPWP and CPWP is calculated by dividing the probability of smoking in CPWP by the probability of smoking in the CNPWP. We adjusted each relative risk analysis with covariates (age, gender, race, and education) using a binary split for each covariate. We did not use multivariate splitting, as it would have reduced sample size, and the resulting statistics might not have been stable or representative. The segments for each covariate were: 1) age <38 or age Ն38, 2) female or male, 3) White or non-White, and 4) high school or lower or some college or higher. We adjusted each family segment of P values with a Bonferroni correction (0.05/24 = 0.002) to control for Type I errors. In addition, the frequency of smoking status was compared by z score for each of these comparisons. This z score (a standard score in a normal distribution) was calculated as the difference between two percentages for independent groups, which is essentially the same as a chi-square calculation, but also provides Bayesian adjusted confidence intervals. For the CPWP, APP, and CPP, student t-tests were used to assess the difference in highest pain score for each of the unique comparisons of nonsmokers, those smoking less than one pack per day, those smoking one pack or more per day, and those smoking any amount per day. For example, among CPWP, the highest pain score was compared between nonsmokers and those smoking less than one pack per day. We adjusted each student t-test analysis with the same covariates and their segments as described for the relative risk analyses. We adjusted each family segment of P values with a Bonferroni correction (0.05/18 = 0.003) to control for Type I errors. We employed an alpha level Յ0.05 for significance. Table 1 presents the demographic characteristics of the data pool subgroups utilized in this study.
Results
Group differences on each of the five demographic characteristics were explored. ANOVA revealed statistically significant (P < .05) mean differences between the groups on age: CPWPs were older on average than the other three groups. APPs and CPPs had a significantly higher proportion of White participants than CNPWPs, and APPs were also significantly higher than the CPWPs. CNPWPs and CPWPs had significantly higher proportions of Black participants than APPs and CPPs. The CNPWPs had a significantly higher proportion of Hispanic participants than any other group. CNPWPs also had a significantly higher proportion of males than any other group. Finally, APPs had a significantly lower proportion of participants with less than a high school education than any other group, APPs and CPPs had a significantly higher proportion of participants with some college education than CPWPs, and CPPs had a significantly lower proportion of participants with college degrees than any other group. Table 2 displays the number of participants who were nonsmokers, smoking less than one pack per day, smoking one pack or more per day, or smoking any amount per day. APP = acute pain patient; BHI-R study = battery for health improvement-R study; CNPWP = community non-patients without pain; CPP = chronic pain patient; CPWP = community patient with pain. For each row, values with the same superscript letter do not differ significantly from each other at P < 0.05. APP = acute pain patient; CNPWP = community non-patients without pain; CPP = chronic pain patient; CPWP = community patient with pain. Table 3 displays the unique relative risks and z scores between the CNPWP and CPWP, APPs, and CPPs, respectively. Relative risks and z scores between the CNPWP and CPWP and APPs were similar, as most relative risk values were at or near 1.0 and the corresponding z scores were nonsignificantly different between the groups. However, the relative risk of not smoking was lower for the CPPs compared to the CNPWP, and smoking one pack/day or more or smoking any amount per day was higher for CPPs compared to the CNPWP according to the respective z scores. Table 4 displays the unique relative risks and z scores between the CPWP and APPs and CPPs, respectively. Relative risks and z scores between the CPWP and APPs were similar, as most relative risk values were at or near 1.0, and the corresponding z scores were nonsignificantly different between the groups. However, the relative risk of not smoking was lower for the CPPs compared to the CPWP, and smoking one pack/day or more or smoking any amount per day was higher for CPPs compared to the CPWP according to the respective z scores. .90) z = 2.14, P = 0.03 z = 0.89, P = 0.37 z = 3.50, P = 0.001 z = 2.14, P = 0.03 APP = acute pain patient; CNPWP = community non-patients without pain; CPP = chronic pain patient; CPWP = community patient with pain; RR = relative risk. White people than Black people (22.2% vs 20.2%); and generally decreases with increasing years of education [12] . As our comparison groups (CPWP, APPs, CPPs) differed for age, race-ethnicity, sex, and education, we undertook additional relative risk sub-analyses of smoking status adjusted by age or sex or race or education. The results of which are presented in Table 6 . Table 6 displays the unique relative risks and z scores between CNPWP and CPWP, CNPWP and APPs, CNPWP and CPPs, CPWP and APPs, CPWP and CPPs, and APPs and CPPs for each binary segment of age or sex or race or education. We utilized a Bonferroni correction (corrected P-value < 0.002 = 0.05/24) to determine significance for each family segment of comparisons. For age <38, the relative risk of smoking one pack/day or more was higher for CPPs compared to the CPWPs. No relative risk was significant for age Ն38. For males, the relative risk of not smoking was lower for the CPPs compared to the CPWPs, smoking one pack/day or more or smoking any amount per day was higher for CPPs compared to the CPWPs according to the respective z scores, and smoking one pack/day or more was higher for CPPs compared to the APPs. No relative risk was significant for females. For White people, the relative risk of not smoking was lower for the CPPs compared to the CPWPs, smoking one pack/day or more or smoking any amount per day was higher for CPPs compared to the CPWPs according to the respective z scores, and smoking one pack/day or more was higher for CPPs compared to the APPs. No relative risk was significant for non-White people. For those who had attained some college or more education, the relative risk of not smoking was lower for the CPPs compared to the CPWPs, and smoking one pack/day or more or smoking any amount per day was higher for CPPs compared to the CPWPs according to the respective z scores. No relative risk was significant for those who had a high school education or less. As our comparison groups differed by age, sex, race, and education, we also performed a number of subanalyses controlling for these variables in the comparison of highest level of pain by smoking status between CPWP, APPs, and CPPs Adjusted by age or gender or race or education. Table 8 displays the means and standard deviations of the highest level of pain score for the CPWP, APPs, and CPPs by smoking status for each binary segment of age or gender or race or education. Student t-tests were used to evaluate all unique two-way comparisons between each smoking status group for each of CPWP, APPs, and CPPs. We utilized a Bonferroni correction (corrected P value < 0.003 = 0.05/18) to determine significance for each family segment of comparisons. For age <38, no differences were noted for any of the smoking groups for CPPs. For CPWPs and APPs, nonsmokers had a lower score on highest level of pain compared to those smoking one pack/day or more and those smoking any amount/ day, respectively. All other comparisons were nonsignificant. For age Ն38, no differences were noted. For females, no differences were noted for any of the smoking groups for APPs or CPPs. For CPWPs, nonsmokers had a lower score on highest level of pain compared to those smoking one pack/day or more and those smoking any amount/day, respectively, and those smoking less than one pack/day had a lower score on highest level of pain compared to those smoking one pack/day or more. For males, no differences were noted for any of the smoking groups for CPPs. For CPWPs, nonsmokers had a lower score on highest level of pain compared to those smoking one pack/day or more and those smoking any amount/ day, respectively. For APPs, nonsmokers had a lower score on highest level of pain compared to those smoking one pack/day or more. For White people, no differences were noted for any of the smoking groups for APPs and CPPs. For CPWPs, nonsmokers had a lower score on highest level of pain compared to those smoking one pack/day or more and those smoking any amount/day, respectively. For non-White people, no differences were noted. For both education categories, no differences were noted.
Frequency of Smoking for CNPWP, CPWP, APPs, and CPPs
Relative Risk and Z Scores of Smoking Status Between CNPWP and CPWP, APPs, and CPPs Not Controlling for Age or Sex or Race or Education
Relative Risk and Z Scores of Smoking Status Between CPWP and APPs and CPPs Not Controlling for Age or Sex or Race or Education
Relative Risk and Z Scores of Smoking Status Between APPs and CPPs Not Controlling for Age or Sex or Race or Education
Highest Level of Pain by Smoking Status for CPWP, APPs, and CPPs
Discussion
The results of the first analysis not controlling for age or sex or race or education indicated that the prevalence of smokers is greater within CPPs than within the comparison groups (CNPWP, CPWP, and APPs). The consistency of the results across these three comparison groups indicated that CPPs are a very different group in reference to smoking prevalence. These results were consistent with the cross-sectional studies presented in the introduction [8, 15, 16] , which indirectly and directly supported this result. As our comparison groups are unique to the literature, these results add significant weight to the results of those previous studies. However, the results of the sub-analyses controlling for age or sex or race or education only partially supported the first result. Controlling for age, CPPs younger than 38 were at greater risk than similar CPWP for using one pack or greater per day, but no differences were demonstrated for other comparisons.
Controlling for gender, all female comparisons were not significant. Male CPPs were at greater risk than male CPWP for using one pack per day or more and any amount. They were also at greater risk for using one pack per day or more vs male APPs. Controlling for ethnicity/ race, White people were at greater risk for using one pack or more per day and any amount than White CPWP. They were also at greater risk for using one pack or more vs White APPs. There were no differences in any comparisons controlling for non-White status or education (high school or less than high school). However, CPPs with some college or above were at greater risk than similar CPWP for smoking one pack or more and any amount. These additional results, although not as definitive as the initial analysis, do still indicate that there may be differences in nicotine consumption between CPPs and some comparison groups with CPPs smoking more. However, future studies in this area will need to control for age, gender, race, and education.
The results of this study in reference to the second question-"Do CPPs who smoke have higher pain levels than nonsmoking CPPs"-indicate that as measured by highest pain, CPPs do not complain of higher pain vs nonsmoking CPPs. This statement is the result of the analyses for the total group and also is supported by the secondary analyses controlling for age or gender or race or education. This overall finding is supported by three previous studies [14, 27, 28] but is in conflict with four other studies [23] [24] [25] [26] . However, it is to be noted that of these seven studies, four were univariate analyses [23] [24] [25] 28] , and three were multivariate analyses [14, 26, 27] . Multivariate studies are a stronger line of evi- dence than univariate studies. Of the multivariate studies, the majority [14, 27] found that pain did not predict smoking status in CPPs, while one [26] did. It is interesting to note that in CPWP, nonsmokers had significantly lower levels of pain than those smoking one pack/day or more and those smoking any amount. In addition, those smoking less than one pack had significantly lower levels of pain than those smoking one pack/ day or more. Similarly in APPs, nonsmokers had significantly lower levels of pain than those smoking one pack/day or more and those smoking any amount. It is difficult to explain these results, especially in the light of the negative pain results for CPPs. However, these results do indicate that if smoking CPPs are proven to have higher pain levels than nonsmoking CPPs, this observation may also be applicable to other subgroups such as APPs. This issue then requires further study.
While the comparisons of highest pain levels in this study suggest that CPWPs and APPs who smoke have higher pain levels, this is not true for those with chronic pain. However, the comparisons of prevalence show that those with chronic pain are more likely to smoke, and to smoke one or more packs of cigarettes a day. This latter finding could be explained in one of two ways: Either those who smoke are less likely to recover from painful conditions, and go on to develop chronic conditions, or those with chronic conditions are somehow more likely to use smoking as a coping strategy for pain than are those with acute conditions. Although these two hypotheses remain to be tested, the first would seem to have more intuitive appeal. If this first hypothesis is true, then it could be that in the early stages of a pain condition, smoking tends to lead to higher levels of pain. Over the course of time, though, when a chronic condition develops, smoking may no longer lead to higher levels of pain, but could prevent painful conditions from resolving.
The question of whether APPs, CPWP, and CPPs who smoke have more pain has significant clinical relevance. This is because nicotine may have an antinociceptive effect [40] . There is also some recent evidence that indicates that pain can be an actual motivator for smoking [41] , possibly because of the antinociceptive effect of nicotine. In addition, there is also some cross-sectional recent evidence that smokers who have more pain smoke more cigarettes [42] . Although this part of our study adds to the knowledge base surrounding this question, it does not definitively answer it. As such, because of the clinical relevance of this question, future researchers should pursue this question further.
There are a number of potential confounders to this study that will be discussed below. First, it is possible that some of the CPPs gave false information about their smoking status. This possibility has previously been reported in the literature by our group [43] in reference to other drugs and could also translate to nicotine reporting. The problem of false information could only have been controlled for by a biochemical analysis, which was not done. Thus, false information in reference to smoking status could have impacted on our findings.
Second, our data did not allow us to identify ex-smokers, never smokers, or light smokers. There is some evidence in the literature that such groups may differentiate from the current smokers and current nonsmokers [44, 45] . As such, the inability to eliminate the above groups could have served as a confounder to our results.
Third, there is a possibility for self-selection bias for entrance into the data pool. As noted in the Methods section, the 777 rehabilitation patients were recruited from various clinics by posters/flyers, ensuring some random selection. However, this procedure did not preclude selfselection bias in entering/not entering the data pool. Similarly, community patients and non-patients were also recruited by newspaper advertisements and posters. Thus, this issue could have served as a potential confounder to the results of this study.
Fourth, the defining criterion for the distinction between acute and chronic utilized in this study was pain duration. This is well accepted in the pain literature. However, this does not mean that the condition is etiologically any different or that the patient knows that he/she has acute pain or chronic pain. Thus, the selection and comparison of these groups for analysis could be premature. However, the fact that CPPs are statistically more likely to be smokers and heavy smokers vs CNPWP, CPWP, and APPs would indicate that the artificial time distinction is tapping different populations of pain patients.
The final potential confounder to the application of these results to current CPP smokers is that of changes in prevalence of smoking within the general population. Smoking prevalence within the U.S. general population has declined over the last 20 years [12] . Our data pool items were collected between 1/95 and 9/95. As such, our data is greater than 10 years old. Consequently, the results of this study may not be applicable to the current CPP population. However, as all the comparison groups came from the same time period, the comparison results are not confounded by this issue. To determine if these comparison results apply to current populations, this study will need to be repeated with current CNPWP, CPWP, AAPs, and CPPs.
What are the clinical implications to this study? The major implication is that pain physicians seeing CPPs should inquire about smoking status and generally should expect a positive smoking status response. If such a response is obtained, the potential implications of smoking status should be discussed with the CPP. The CPP should be asked if he/she had increased their smoking with the onset of chronic pain. If there has been an increase, the reasons for this should be explained. Finally, the CPP should be offered smoking cessation treatment.
Conclusions
This study has demonstrated that the prevalence of smokers within CPPs is significantly greater than some comparison groups. According to our results, CPPs who smoke do not have higher pain levels than nonsmoking CPPs.
